Moderna Inc

NASDAQ:MRNAUnited States

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.

Contact Information

Headquarters

325 BINNEY STREETCambridge, MA, United States 02142

Phone

617-714-6500

Fax

617-583-1998

Executives

Non-Executive Independent Chairman of the Board, Co-Founder

Noubar Afeyan

President

Stephen Hoge

Director

Stephane Bancel

Chief Financial Officer

James Mock

Chief Technical Operations and Quality Officer

Jerh Collins